Hangzhou Haoyang Biotechnology Co., Ltd. berfokus pada penyediaan antibodi, protein fusi, dan produk jenis ADC kepada pelanggan, dari penilaian kemampuan obat awal, studi farmasi IND hingga layanan penelitian dan pengembangan dan produksi satu atap untuk produksi komersial. Berbasis di Tiongkok, melayani pelanggan global.
'%3e%3cpath%20id='Vector'%20d='M11.3577%208.14503C11.447%208.23841%2011.5544%208.31273%2011.6732%208.3635C11.792%208.41428%2011.9199%208.44045%2012.0492%208.44045C12.1784%208.44045%2012.3063%208.41428%2012.4251%208.3635C12.544%208.31273%2012.6513%208.23841%2012.7407%208.14503L15.7036%205.19111C15.7972%205.10234%2015.8718%204.99543%2015.9228%204.87689C15.9738%204.75835%2016%204.63066%2016%204.50163C16%204.37259%2015.9738%204.24491%2015.9228%204.12637C15.8718%204.00783%2015.7972%203.90091%2015.7036%203.81215L12.7397%200.858226C12.6503%200.764845%2012.543%200.690527%2012.4241%200.639754C12.3053%200.588981%2012.1774%200.562805%2012.0482%200.562805C11.9189%200.562805%2011.791%200.588981%2011.6722%200.639754C11.5534%200.690527%2011.446%200.764845%2011.3567%200.858226L8.39478%203.81315C8.30112%203.90191%208.22654%204.00883%208.17556%204.12737C8.12459%204.24591%208.0983%204.37359%208.0983%204.50263C8.0983%204.63166%208.12459%204.75935%208.17556%204.87789C8.22654%204.99643%208.30112%205.10334%208.39478%205.19211L11.3577%208.14603V8.14503ZM6.41983%200.809227H0.987974C0.726546%200.809489%200.475858%200.913252%200.29072%201.09783C0.105582%201.2824%200.00105721%201.53278%200%201.7942L0%207.20906C0%207.75104%200.443988%208.19403%200.987974%208.19403H6.41983C6.68108%208.1935%206.93151%208.08962%207.11644%207.90508C7.30136%207.72053%207.40575%207.47031%207.4068%207.20906V1.7942C7.40575%201.53295%207.30136%201.28273%207.11644%201.09818C6.93151%200.913633%206.68108%200.809753%206.41983%200.809227ZM6.41983%207.20906H0.987974V1.7942H6.41983V7.20906ZM6.41983%209.179H0.987974C0.726719%209.17926%200.47618%209.28289%200.291071%209.46725C0.105961%209.65161%200.00132068%209.90172%200%2010.163L0%2015.5778C0%2016.1198%200.443988%2016.5628%200.987974%2016.5628H6.41983C6.68108%2016.5623%206.93151%2016.4584%207.11644%2016.2739C7.30136%2016.0893%207.40575%2015.8391%207.4068%2015.5778V10.163C7.40575%209.90172%207.30136%209.6515%207.11644%209.46696C6.93151%209.28241%206.68108%209.17853%206.41983%209.178V9.179ZM6.41983%2015.5788H0.987974V10.163H6.41983V15.5778V15.5788ZM14.8146%209.179H9.38275C9.12149%209.17926%208.87096%209.28289%208.68585%209.46725C8.50074%209.65161%208.3961%209.90172%208.39478%2010.163V15.5778C8.39478%2016.1198%208.83976%2016.5628%209.38275%2016.5628H14.8146C15.0759%2016.5623%2015.3263%2016.4584%2015.5112%2016.2739C15.6961%2016.0893%2015.8005%2015.8391%2015.8016%2015.5778V10.163C15.8005%209.90172%2015.6961%209.6515%2015.5112%209.46696C15.3263%209.28241%2015.0759%209.17853%2014.8146%209.178V9.179ZM14.8146%2015.5788H9.38275V10.163H14.8146V15.5778V15.5788Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_132_1117'%3e%3crect%20width='16'%20height='16'%20fill='white'%20transform='translate(0%200.562805)'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Skenario AplikasiPerusahaan domestik memulai, dan individu di luar negeri menandatangani laporan pengujian, surat kuasa, dan dokumen terkait lainnya, pengujian genetik kerja sama domestik dan luar negeri, dan bisnis penelitian dan pengembangan obat
'%3e%3cpath%20d='M5.4%2013.6128H10.5625C10.8375%2013.6128%2011.0875%2013.8253%2011.0875%2014.1378C11.0875%2014.4128%2010.875%2014.6628%2010.5625%2014.6628H5.4C5.125%2014.6628%204.875%2014.4503%204.875%2014.1378C4.875%2013.8253%205.0875%2013.6128%205.4%2013.6128ZM10.1375%2015.4378H5.825C5.75%2015.4378%205.725%2015.5378%205.7875%2015.6128L7.3625%2016.4253C7.5375%2016.5003%207.75%2016.5628%208%2016.5628C8.2125%2016.5628%208.3875%2016.4878%208.6%2016.4253L10.175%2015.6128C10.25%2015.5503%2010.2125%2015.4378%2010.1375%2015.4378ZM7.9%204.03781C8.5375%204.03781%209.0875%204.28781%209.65%204.81281C10.2125%205.30031%2010.4625%205.93781%2010.4625%206.71281C10.4625%206.96281%2010.675%207.23781%2010.9875%207.23781C11.2625%207.23781%2011.5125%206.98781%2011.5125%206.71281C11.5125%205.58781%2011.1625%204.71281%2010.425%204.05031C9.6875%203.38781%208.85%203.06281%207.9%203.06281C7.625%203.06281%207.375%203.27531%207.375%203.58781C7.4%203.78781%207.6125%204.03781%207.9%204.03781Z'%20fill='white'/%3e%3cpath%20d='M10.2747%2012.7378H5.68715C5.16215%2012.7378%204.73715%2012.3503%204.67465%2011.8253C4.59965%2011.7253%204.42465%2011.4753%204.36215%2011.4003C2.84965%2010.2378%201.97465%208.48781%201.97465%206.58781C1.96215%203.26281%204.66215%200.562805%207.99965%200.562805C11.3372%200.562805%2014.0372%203.2628%2014.0372%206.60031C14.0372%208.5253%2013.1622%2010.2878%2011.6122%2011.4378C11.5372%2011.5128%2011.3622%2011.7128%2011.2997%2011.8628C11.2247%2012.3128%2010.8122%2012.7378%2010.2747%2012.7378ZM5.82465%2011.5503H10.1372C10.2372%2011.1253%2010.6622%2010.6378%2010.8747%2010.4628C12.0997%209.5503%2012.7997%208.11281%2012.7997%206.56281C12.7997%203.90031%2010.6247%201.72531%207.96215%201.72531C5.29965%201.72531%203.12465%203.90031%203.12465%206.56281C3.12465%208.10031%203.82465%209.5128%205.04965%2010.4253C5.26215%2010.6003%205.71215%2011.0878%205.82465%2011.5503Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_132_1239'%3e%3crect%20width='16'%20height='16'%20fill='white'%20transform='translate(0%200.562805)'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Solusi'%20stroke-width='2'%20stroke-linecap='round'%20stroke-linejoin='round'/%3e%3cdefs%3e%3clinearGradient%20id='paint0_linear_132_1162'%20x1='2.16602'%20y1='11.8961'%20x2='13.666'%20y2='11.8961'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%231063F1'/%3e%3cstop%20offset='1'%20stop-color='%231063F1'%20stop-opacity='0.5'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e)
Perusahaan domestik memulai penandatanganan melalui eSignGlobal, dan orang yang bertanggung jawab atas mitra luar negeri menerima tautan ke dokumen yang akan ditandatangani melalui email, dan memasuki penandatanganan melalui otentikasi email
Penandatanganan bersama di luar negeri menyediakan saluran kerja sama yang lebih lancar untuk penelitian dan pengembangan obat dan bisnis pengujian
